
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings, Inc. has reported record quarterly revenue growth in its core oncology business, enhanced by a new contract with a large hospital system expected to increase patient volumes in the upcoming quarter. The company's gross profit margin improved significantly by 370 basis points to 55.2%, attributed to an optimized revenue mix and normalized costs, which reflects operational efficiency. Additionally, year-to-date net operating cash flow reached $17.3 million, showing a 38% increase that underscores improved earnings and effective working capital management, setting a positive trajectory for future growth.
Bears say
InfuSystems Holdings Inc. is facing a challenging financial landscape characterized by declining gross margins, particularly within its Device Solutions division, alongside rising operational costs. Economic uncertainties have exacerbated this situation, leading to customer destocking that has reduced both demand and sales volumes, thereby exerting further pressure on margins. Revenue estimates for FY26 have been adjusted downward by $9.5 million, remaining flat compared to FY25, highlighting the company's struggles amid competitive headwinds and decreasing sales productivity.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares